Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

Sponsor
First Affiliated Hospital of Jinan University
Study ID
NCT03948347
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.

Study Details

The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS ≤ 3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥ 4 ) patients with type 2 diabetes mellitus.

Key Dates

Start date
Jun 25, 2019
Status verified
Feb 2023
Primary completion
Dec 31, 2023
Completion
Jun 30, 2024

Study Design

Enrollment
1,708 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: active
    Active patients will receive liraglutide injections
  • No Intervention: standard care/no intervention
    standard care for stroke as per hospital protocol

Primary Outcome Measure

Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic) [ Time Frame: 90 days ]

Central Contacts

Related Studies